SCHEMBL5687989

SCHEMBL5687989

O=C(O)Cc1ccc(OCC2CCN(C(=O)Oc3ccc4cccnc4c3)CC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.44
PPARG P37231 1/20 0.43
GRIN2B Q13224 3/20 0.43
LMNA P02545 2/20 0.42
KDM4E B2RXH2 1/20 0.42
TNF P01375 1/20 0.42
MAPT P10636 1/20 0.42
RAB9A P51151 1/20 0.42
NOD1 Q9Y239 1/20 0.42
GRIN2D O15399 1/20 0.40
GRIN3B O60391 1/20 0.40
GRIN1 Q05586 1/20 0.40
GRIN2A Q12879 1/20 0.40
GRIN2C Q14957 1/20 0.40
GRIN3A Q8TCU5 1/20 0.40
CYP3A4 P08684 1/20 0.40
CHEK2 O96017 1/20 0.39
ALDH1A1 P00352 1/20 0.38
HRH1 P35367 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5688360 0.89 CHEK2 (0.43) MGLLGRIN2BLMNAKDM4ETNF
SCHEMBL5689887 0.88 EPHX2 (0.48) CYP3A4ALDH1A1HRH1
SCHEMBL5687234 0.84 LIPE (0.45) MGLLGRIN2BLMNAKDM4ETNF
SCHEMBL5210523 0.82 MAPT (0.50) PPARGGRIN2BLMNAKDM4ETNF
SCHEMBL5688338 0.81 LIPE (0.47) MGLLGRIN2BLMNAKDM4ETNF
SCHEMBL5688383 0.80 GRIN2B (0.43) MGLLGRIN2BKDM4ERAB9ACYP3A4
SCHEMBL5686932 0.80 LMNA (0.42) MGLLGRIN2BLMNAKDM4ETNF
SCHEMBL5690381 0.80 GRIN2B (0.46) MGLLGRIN2BRAB9A
SCHEMBL5714535 0.79 HSD17B10 (0.42) KDM4ERAB9ACYP3A4ALDH1A1
SCHEMBL5931487 0.79 GRIN2B (0.45) MGLLGRIN2BLMNARAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160851-A1 Substituted piperidine carbamates LIPE, PNLIP, LIPC MGLL 39/4885PPARG 64/4885GRIN2B 2588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.